Ultherapy PRIME for Knees: The 2026 Laxity Clearance, Limits, and Who It Will Not Help

On 11 August 2026, Merz Aesthetics announced that the U.S. Food and Drug Administration (FDA) cleared Ultherapy PRIME (Ulthera System, product code OHV, 21 CFR 878.4590) for a new clinical indication: to improve the appearance of skin laxity on the knees.

This regulatory milestone makes the knee region the latest anatomical addition to the Ultherapy PRIME platform's cleared body portfolio, which already includes the abdomen, anterior arms, and posterior arms.

However, widespread misinterpretation on social media and clinic blogs has already begun:

1. This is a 510(k) clearance, not a Premarket Approval (PMA) or "FDA approval." (Several trade publications mistakenly reported "FDA approval.")
2. It is indicated strictly for the appearance of skin laxity, not for fat reduction or joint disease.
3. It does not replace a surgical thigh or knee lift when substantial, hanging redundant skin folds are present.
4. Body skin results have different longevity than facial lifting. Merz's clinical materials note body laxity improvements lasting up to about six months, compared to a year or more for facial and submental lifting.

This guide provides an evidence-based breakdown of the 2026 knee indication, the underlying 510(k) regulatory lineage, clinical mechanisms, anatomical limits, skin-of-color safety, and realistic candidate selection.

---

Direct Comparison: Ultherapy PRIME for Knees vs. Alternative Modalities

---

What Did the FDA Actually Clear? 510(k) Clearance vs. Approval

In aesthetic device regulation, the distinction between 510(k) Clearance and Premarket Approval (PMA) is fundamental. For a detailed breakdown of how device claims are verified, see our guide on FDA cleared vs FDA registered aesthetic devices.

Ultherapy PRIME is a Class II medical device regulated under 21 CFR 878.4590 (Focused ultrasound stimulator system for aesthetic use, product code OHV). It enters the market via Section 510(k) of the Federal Food, Drug, and Cosmetic Act by demonstrating substantial equivalence in safety and effectiveness to legally marketed predicate devices.

Current Ultherapy PRIME Indications for Use (IFU)

Following the 11 August 2026 expansion, the official manufacturer Instructions for Use statement includes:

• Face & Neck (Lifting Indications): Non-invasive dermatological aesthetic treatment to:
  1. Lift the eyebrow (Upper face)
  2. Lift lax submental (beneath the chin) and neck tissue
  3. Improve lines and wrinkles of the décolleté
• Body (skin-laxity appearance indications): Non-invasive treatment to improve the appearance of skin laxity on:
  1. Abdomen
  2. Anterior arms
  3. Posterior arms
  4. Knees (added in the 11 August 2026 IFU statement)

The wording split matters: face/neck claims are lift (eyebrow, submental/neck) plus décolleté lines; body claims are improve the appearance of skin laxity. Knees sit in the body column.

Critical safety note: The knee clearance is strictly for the appearance of skin laxity. The device is not cleared or approved to treat osteoarthritis, joint inflammation, patellar tendinitis, subcutaneous lipomas, or infrapatellar fat deposits.

---

Regulatory Lineage: The Ulthera 510(k) Timeline

The Ulthera System has maintained a continuous regulatory lineage since the first De Novo classification in 2009. Reviewing the historical 510(k) database entries clarifies how the platform evolved:

• DEN080006 (11 September 2009): Original De Novo classification establishing product code OHV for non-invasive eyebrow lifting.
• K121700 (2 October 2012): 510(k) clearance expanding indications to lift lax submental and neck tissue.
• K134032 (20 June 2014): Clearance for improving lines and wrinkles of the décolleté.
• K233996 (22 February 2024): Clearance of the UC-1 Control Unit (Ultherapy PRIME), modernizing the processing hardware, screen resolution, and imaging refresh rate.
• K243035 (Decision Date: 24 February 2025): 510(k) clearance expanding the platform to body skin laxity on the arms and abdomen. (Note: While manufacturer press discussed body expansion in late 2025, the FDA 510(k) database records the official decision date on 24 February 2025. This article cites the official FDA decision date.) For background on the initial body expansion, see Ultherapy PRIME FDA clearance for arms and abdomen.
• K250418 (13 May 2025): Clearance for PRIME Model 2.1 system enhancements.
• K260618 (21 May 2026): Additional system modification clearance.
• August 2026 Knee Clearance: Merz announced clearance on 11 August 2026. Official public indexing of 510(k) summary PDFs in the FDA CDRH database typically experiences an administrative lag of several weeks.

Legacy Platform Sunset Date

In its August 2026 commercial announcement, Merz Aesthetics also confirmed that official customer support, transducer supply, and service for the first-generation legacy Ultherapy system will formally conclude on 30 September 2027, as clinics transition to Ultherapy PRIME.

---

Anatomy of Knee Skin Laxity: Why Knees Age Differently

The skin surrounding the human knee joint is subjected to unique biomechanical stresses that make it distinct from facial or abdominal skin.

Mild crepey laxity — thin, accordion-like folding above the kneecap with an intact musculoskeletal envelope — is the presentation MFU-V is positioned for. Severe redundant hanging skin after large weight loss is a surgical problem; energy devices cannot excise excess.

1. High-frequency mechanical folding

The knee joint undergoes continuous flexion and extension throughout daily life. The suprapatellar skin (directly above the kneecap) must stretch to accommodate a 130°–140° bend and retract when the leg straightens. Over decades, repeated mechanical deformation fractures fragmented elastic fibers, creating characteristic horizontal "accordion" lines.

2. Dermal Thinning and Elastosis

Unlike facial skin, which contains a high density of sebaceous glands and hair follicles that support epidermal turnover, knee skin has fewer pilosebaceous units. Sun exposure (photoaging) combined with chronological decline in fibroblast activity leads to a thin, crepey epidermal and dermal envelope.

3. Rapid Weight Loss (GLP-1 "Ozempic Body")

The widespread adoption of GLP-1 receptor agonists (such as semaglutide and tirzepatide) has created a surging patient cohort with rapid loss of subcutaneous volume. When subcutaneous adipose tissue deflates quickly, the overlying skin envelope fails to retract, resulting in noticeable suprapatellar skin puddling. While GLP-1-related laxity is a prominent commercial driver, it represents a clinical presentation rather than a separate FDA-labeled subpopulation. To understand generalized cutaneous thinning, explore our guide on crepey skin causes, treatments, and evidence.

---

Mechanism of Action: How Micro-Focused Ultrasound Works on the Knee

Ultherapy PRIME utilizes Micro-Focused Ultrasound with Visualization (MFU-V).

1. Real-Time DeepSEE Ultrasound Imaging

The critical differentiator between MFU-V and bulk-heating devices (such as monopolar radiofrequency) is real-time diagnostic imaging. Using the integrated DeepSEE transducer, the provider visualizes tissue layers down to 8 mm beneath the surface.

On the knee, this visualization is vital: it allows the clinician to ensure energy is deposited into the deep reticular dermis and subcutaneous connective tissue while strictly avoiding the periosteum of the patella, joint capsule, and superficial bursa.

2. Thermal Coagulation Points (TCPs)

The transducer focuses acoustic waves to precise microscopic focal points, generating temperatures between 60°C and 70°C—the optimal thermal zone for protein denaturation:

• Immediate Phase: Existing triple-helix collagen fibers immediately contract.
• Delayed Phase (Neocollagenesis & Neoelastogenesis): The controlled micro-thermal injury initiates a wound-healing cascade. Fibroblasts synthesize new Type I and Type III collagen and elastin fibers over 60 to 180 days.

3. Transducer Depth Selection on the Knee

On the knee, providers typically utilize:

• 1.5 mm Transducer (10 MHz): Targets the superficial papillary and upper reticular dermis to smooth fine, superficial crepey wrinkles.
• 3.0 mm Transducer (7 MHz): Targets the mid-to-deep reticular dermis and fibrous septae to improve structural recoil.
• 4.5 mm Transducer (4 MHz): Used selectively in patients with adequate subcutaneous depth, avoiding direct bony contact over the patella.

For a broader evaluation of ultrasound versus radiofrequency technologies, see our head-to-head comparison of Ultherapy vs Sofwave vs Thermage.

---

Body vs. Face Longevity: Managing Durability Expectations

A critical clinical detail disclosed in Merz's regulatory communications is the expected duration of results on body tissue.

• Facial / neck lifting: Manufacturer materials describe results that can last a year or more. That is not a guaranteed individual duration, and it is not the body claim.
• Body indications (knees, arms, abdomen): Merz’s 11 August 2026 footnotes state body results can last up to 6 months.

Why does body skin often have a shorter manufacturer duration window?

1. Gravitational & Mechanical Load: The knee carries substantial biomechanical strain and constant tensile loading during ambulation, accelerating the structural fatigue of newly synthesized collagen.
2. Subcutaneous Architecture: Body skin lacks the dense superficial muscular aponeurotic system (SMAS) found in the face; tightening relies primarily on dermal and fibrous septal remodeling.
3. Expectation Management: Patients should understand that knee Ultherapy is not a permanent fix. Most patients require touch-up maintenance treatments every 6 to 12 months to preserve clinical improvement.

---

Candidacy: Who Will Knee Ultherapy NOT Help?

Proper patient selection determines procedural success. MFU-V is a targeted collagen stimulator; it is not a panacea for all knee-area aesthetic complaints.

1. Patients with severe, hanging skin excess (surgical candidates)

If a patient has heavy, redundant skin folds that drape over the top of the patella (frequently seen after massive weight loss of 50+ lbs), non-invasive energy devices cannot deliver meaningful improvement. Acoustic coagulation cannot excise 4 cm of redundant skin. These patients require a surgical thigh lift (thighplasty) or localized surgical knee lift.

2. Patients with Subcutaneous Fat Deposits (Infrapatellar Fat Pads)

Many patients present complaining of "fat knees" or prominent medial/infrapatellar fat pads. Ultherapy PRIME at labeled aesthetic fluences is designed to tighten dermis and fibrous septae, not perform bulk lipolysis. Patients seeking volume debulking are better served by cryolipolysis, deoxycholic acid injections, or liposuction.

3. Patients with Knee Joint Disease (Osteoarthritis, Bursitis)

Ultherapy PRIME carries zero orthopedic indication. It does not treat patellofemoral syndrome, meniscal tears, cartilage wear, or joint pain. In patients with active prepatellar bursitis or severe rheumatoid inflammation, energy delivery over the joint is contraindicated.

4. Patients with Lipedema or Lymphedema

Lipedema is a chronic adipose tissue disorder characterized by abnormal, painful fat accumulation and capillary fragility in the lower extremities. MFU-V does not treat the underlying pathophysiology of lipedema and should not be marketed as a treatment for diseased lymphatic or lipedemic tissue.

---

Skin of Color Safety: Fitzpatrick IV–VI Considerations

One of the significant clinical advantages of Micro-Focused Ultrasound over laser resurfacing (e.g., CO₂, Erbium, Fractional Thulium) and Intense Pulsed Light (IPL) is its favorable safety profile in skin of color (Fitzpatrick phototypes IV, V, and VI).

Optical Lasers vs. Acoustic Ultrasound

• Lasers & IPL: Deliver optical photons absorbed by chromophores (melanin, hemoglobin, water). In melanin-rich epidermis, competitive absorption of optical energy by epidermal melanocytes creates high risk of thermal blisters, hypopigmentation, and stubborn post-inflammatory hyperpigmentation (PIH).
• MFU-V Acoustic Energy: Acoustic ultrasound waves pass entirely through the epidermal layer without absorption by melanin pigment. Thermal coagulation points are generated strictly at the selected focal depth (1.5 mm or 3.0 mm) beneath the melanocyte-bearing basal layer.

Adverse Events & Neurological Safety

While PIH risk is low, providers and patients must observe standard clinical precautions:

• Transient Erythema & Edema: Mild redness (lasting 1 to 4 hours) and mild swelling (lasting 2 to 7 days) are standard tissue responses.
• Transient Nerve Irritation: The knee contains superficial sensory nerves, including the infrapatellar branch of the saphenous nerve and branches of the lateral femoral cutaneous nerve. High acoustic energy placed directly over superficial nerve branches can cause transient tingling, localized paresthesia, or numbness. In clinical studies, these sensory changes are transient and resolve spontaneously over 2 to 6 weeks.
• Bone Discomfort: When energy pulses near the patella, patients may feel a momentary deep, dull ache as acoustic waves reflect off the periosteum. Experienced providers adjust handpiece placement to maintain energy within the soft-tissue envelope.

---

Cost Comparison: Pricing Knee Ultherapy

Knee skin tightening is an elective aesthetic procedure and is not covered by insurance.

As of 25 August 2026, there is no published US national cash-fee series specific to the new knee indication. Do not treat any single clinic quote as a national average. On this site, the nearest established Ultherapy body comparators remain:

• Arms: about $1,500–$2,500
• Abdomen: about $2,000–$3,500

Knee price will be line-count and market specific. Ask how many transducer lines will be delivered across both knees and what a maintenance session costs if body duration is closer to six months than to a year. For face/neck/arm/abdomen bands, see the Ultherapy cost guide.

---

Questions to Ask Your Provider Before Booking Knee Ultherapy

Before paying a deposit for knee skin tightening, ask your clinician these direct questions:

1. "Are you treating me with the Ultherapy PRIME system, and what transducer depths (1.5 mm, 3.0 mm) will you use on my knees?"
   Why to ask: Ensures the practice is using the updated PRIME platform with real-time visualization rather than un-imaged bulk ultrasound.
2. "How do you use real-time DeepSEE ultrasound imaging to ensure you avoid treating directly over the patella bone and joint capsule?"
   Why to ask: Verifies anatomical safety to minimize periosteal pain and prevent nerve irritation.
3. "Is my knee laxity mild-to-moderate (crepey skin) or do I have surgical-grade skin redundancy that requires excision?"
   Why to ask: Prevents cosmetic disappointment if you are actually a candidate for surgery.
4. "What is your realistic expectation for how long my body skin tightening will last, and what is the cost for a 6-to-12-month maintenance session?"
   Why to ask: Establishes honest expectations regarding the ~6-month body duration window.
5. "How many total lines will you deliver across both knees during my treatment session?"
   Why to ask: Protects against "under-treating," where a clinic delivers too few lines to trigger therapeutic neocollagenesis.

---

Frequently Asked Questions

Is Ultherapy FDA approved for knees?

Ultherapy PRIME is FDA-cleared (via 510(k) Premarket Notification), not FDA-approved. On 11 August 2026, Merz Aesthetics announced clearance to improve the appearance of skin laxity on the knees.

Does Ultherapy work on knees?

Yes, for mild-to-moderate skin laxity and superficial crepey wrinkling above the kneecap. It works by stimulating new collagen in the deep dermis. It does not reduce knee fat or fix heavy, hanging skin folds.

How much does Ultherapy for knees cost?

There is no established US national cash band for the knee indication as of 25 August 2026. Ask for a quote based on transducer line count. The nearest on-site body comparators are arms about $1,500–$2,500 and abdomen about $2,000–$3,500.

What is the downtime for knee Ultherapy?

There is virtually zero social downtime. Patients can resume normal walking, exercise, and daily activities immediately, though mild tenderness, swelling, and minor bruising may persist for several days.

Is Ultherapy PRIME different from legacy Ultherapy for knees?

Yes. Ultherapy PRIME features upgraded software, faster imaging frame rates, and higher-resolution DeepSEE screens. The specific knee skin-laxity indication is cleared for the PRIME platform; legacy Ultherapy platform support concludes in September 2027.

Can Ultherapy tighten knee skin after Ozempic or weight loss?

Yes, if the weight loss resulted in mild-to-moderate crepey deflation without severe hanging tissue aprons. If substantial redundant folds are present, surgical excision is required.

---

Sources

• Merz Aesthetics, Corporate Newsroom: Merz Aesthetics Announces New Knee Indication for Ultherapy PRIME (11 August 2026): https://merzaesthetics.com/news/merz-aesthetics-announces-new-knee-indication-for-ultherapy-prime
• U.S. Food and Drug Administration, 510(k) Premarket Notification Database: Ulthera System K260618 (Decision Date 21 May 2026): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K260618
• U.S. Food and Drug Administration, 510(k) Premarket Notification Database: Ulthera System Body Clearance K243035 (Decision Date 24 February 2025): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K243035
• U.S. Food and Drug Administration, 510(k) Premarket Notification Database: Ulthera System UC-1 Control Unit PRIME K233996 (Decision Date 22 February 2024): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K233996
• Journal of the American Academy of Dermatology (JAAD): Nonsurgical tightening of skin laxity on the knees with intense focused ultrasound (JAAD 2014): https://www.jaad.org/article/S0190-9622(14)00803-2/fulltext
• American Med Spa Association (AmSpa), Industry Reports: Merz Aesthetics Ultherapy PRIME Gains FDA Clearance for Knee Skin Laxity (11 August 2026): https://www.americanmedspa.org/news/merz-aesthetics-ultherapy-prime-gains-fda-clearance-for-knee-skin-laxity/
• U.S. FDA Aesthetic Cosmetic Devices Guidance & Product Code OHV (21 CFR 878.4590): https://www.fda.gov/medical-devices/products-and-medical-procedures/aesthetic-cosmetic-devices